Entera Bio Ltd. (NASDAQ:ENTX)
Industry: PharmaceuticalsMajor

OFF LIST - 2591 consecutive market days: OFF LIST as of 02/21/2006 Through 11/14/2016

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union fractures. The company was founded in 2010 and is headquartered in Jerusalem, Israel.

Current Quote*
Last: $2.500
Change: -0.340
Book: $3.842
Volume: 10,614

As Of: 08/16 13:13 ET
*Quotes delayed by 20min.

Graphs for ENTX


3 Month Graph


6 Month Graph


1 Year Graph